EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Initiation of vedolizumab did not provoke new‐onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24‐week study with imaging assessments

Sherry Rohekar, Tristan Boyd, Robert G Lambert, Melanie Beaton, Nilesh Chande, Jamie Gregor, Heather Lennox, Keith Mcintosh, Terry Ponich, Adam Rahman, Trimadhu Sharma iD, Michael Sey und 2 weitere

United European Gastroenterology Journal · 2024

DOI: 10.1002/ueg2.12621 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift United European Gastroenterology Journal, 2024. Verfasst von Sherry Rohekar und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Rheumatology, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Magnetic Resonance Imaging, Spondylarthritis. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: SPARCC Research Pilot Project Program.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

A temporal relationship between vedolizumab and new‐onset spondyloarthritis (SpA) has been suggested.

Aims

We evaluated the relationship between vedolizumab initiation and development of new‐onset SpA in patients with inflammatory bowel disease (IBD) through serial clinical evaluation and magnetic resonance imaging (MRI).

Methods

A single‐centre prospective observational study of 24 patients with IBD. Patients were eligible if they had active ulcerative colitis or Crohn's disease (CD), were initiating vedolizumab, had no prior history of arthritis or SpA and were suitable for serial MRI. A rheumatologist performed clinical evaluation prior to the first dose and 8 and 24 weeks. Axial MRI was evaluated by a blinded central reader and performed at baseline 8 and 24 weeks.

Results

Nine tumor necrosis factor (TNF) inhibitor‐naïve patients (4 male; mean age 53.2 years; 6 UC; 3 CD) and eight TNF inhibitor‐experienced patients (7 male; mean age 48 years; 3 UC; 5 CD) completed all assessments. No patients developed new features of axial arthritis or features of peripheral SpA (inflammatory oligoarthritis, enthesitis, dactylitis, or psoriasis (nail, body, or scalp)). Both groups demonstrated a good intestinal response.

Conclusion

Vedolizumab initiation did not induce new features of axial or peripheral SpA after 24 weeks of treatment in TNF inhibitor‐experienced or TNF inhibitor‐naive patients with IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedMagnetic Resonance ImagingSpondylarthritisHumansMaleFemaleMiddle AgedProspective StudiesAdultGastrointestinal AgentsInflammatory Bowel DiseasesCrohn Disease

Stichwörter der Autor:innen

Crohn's diseaseinflammatory bowel diseasespondyloarthritisulcerative colitis (UC)vedolizumab

Substanzen

Antibodies, Monoclonal, HumanizedvedolizumabGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Medicine, Division of Rheumatology, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
  • Lawson Health Research Institute, London, Ontario, Canada.
  • Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada.
  • Department of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada.
  • Southwestern Ontario Inflammatory Bowel Disease Clinic, London, Ontario, Canada.
  • London Health Sciences Centre, London, Ontario, Canada.

ORCID-Profile: Trimadhu Sharma, Vipul Jairath

Förderung

  • SPARCC Research Pilot Project Program

Zitieren

APA

Rohekar, S., Boyd, T., Lambert, R. G., Beaton, M., Chande, N., Gregor, J., Lennox, H., Mcintosh, K., Ponich, T., Rahman, A., Sharma, T., Sey, M., Tauqir, M., & Jairath, V. (2024). Initiation of vedolizumab did not provoke new‐onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24‐week study with imaging assessments. United European Gastroenterology Journal. https://doi.org/10.1002/ueg2.12621

Vancouver

Rohekar S, Boyd T, Lambert RG, Beaton M, Chande N, Gregor J, et al. Initiation of vedolizumab did not provoke new‐onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24‐week study with imaging assessments. United European Gastroenterology Journal. 2024. doi:10.1002/ueg2.12621

BibTeX
@article{Rohekar2024,
  author = {Rohekar, Sherry and Boyd, Tristan and Lambert, Robert G and Beaton, Melanie and Chande, Nilesh and Gregor, Jamie and Lennox, Heather and Mcintosh, Keith and Ponich, Terry and Rahman, Adam and Sharma, Trimadhu and Sey, Michael and Tauqir, Maria and Jairath, Vipul},
  title = {Initiation of vedolizumab did not provoke new‐onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24‐week study with imaging assessments},
  journal = {United European Gastroenterology Journal},
  year = {2024},
  doi = {10.1002/ueg2.12621}
}
Kostenlos starten →